Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Etoposide × Gynecologic × Clear all

Phase

Status

Sponsor Class

OTHER 21 NETWORK 5 INDUSTRY 4 NIH 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3 Plasma cell 2 Other hematologic neoplasm 2 Lymphoid 2 NET 1 Gynecologic 1 Gastrointestinal 1 Endocrine 1

Conditions

Ovarian Neoplasms 1 Fallopian Tube Neoplasms 1

Interventions

apatinib 5 Cisplatin 5 Paclitaxel 4 Hydralazine 4 Gemcitabine 4 Valproic Acid 3 Surgical Procedures, Operative 3 Hyperthermic Intraperitoneal Chemotherapy 3 Drug Therapy 3 Carboplatin 3 Bevacizumab 3 pembrolizumab 2 cetrorelix 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Probiotics 2 Poly(ADP-ribose) Polymerase Inhibitors 2 Neoadjuvant Therapy 2 Metformin 2 Laparoscopy 2 Curcumin 2 CP protocol 2 taxane 1 spartalizumab 1 piperine 1 olaparib 1 nimotuzumab 1 lenvatinib 1 fluzoparib 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01669226 2016-12-19

AICE

Shanghai Gynecologic Oncology Group

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡